Goldman Sachs provides a 1Q26 sector check-in for European Healthcare, highlighting robust earnings beats but maintaining a cautious stance on sector-wide re-rating due to looming patent expirations.
Key Takeaways
- 1.1Q26 reporting for European Pharma and Biotech suggests robust earnings momentum, with a 40% revenue and 70% earnings beat rate compared to consensus.
- 2.AstraZeneca is identified as the innovation leader in the sector based on catalyst delivery, pipeline optionality, and Phase 3 success rates.
- 3.The EU large-cap Pharma sector trades at a 10% P/E discount to the broader European market (SXXP), narrowing from previous lows.
Table of Contents
- Monitoring earnings momentum
- GSe vs consensus
- Monitoring innovation momentum
- Catalyst readout summary:
- M&A developments
- Key stock debates and forward catalysts
- Valuation and risks
- Disclosure Appendix
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Rajan SharmaJames QuigleyShyam Kotadia
Securities
AZNBayerNOVNNOVO.B-DK
Themes
Innovation as a Valuation DriverLoss of Exclusivity (LoE) CliffAI-Integrated Drug Discovery
Regions
EuropeUnited KingdomSwitzerlandDenmark